Natasha Hernday is the Chief Business Officer, and a member of the Executive Committee at Seagen, Inc. She leads technology licensing, clinical and commercial collaborations, mergers and acquisitions, Alliance Management, and corporate strategy projects, and serves on the Board of Directors for XOMA Corporation and Alpine Immune Sciences. Prior to joining Seagen in January 2011, she spent more than 16 years at Amgen, in roles of increasing responsibility in research, project management and business development finance, before joining the corporate development group in 2000. While in corporate development, she was a senior member of the mergers and acquisitions team for approximately seven years, followed by two years of sell-side experience leading Amgen’s out-licensing efforts and serving on the board of two companies for Amgen’s Venture Fund. Ms. Hernday received a B.A. in Biology from the University of California Santa Barbara and an M.B.A from Pepperdine University.